Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Academic Health Partners (OAHP) is delighted to have been designated as an NIHR/NHSE/I Academic Health Science Centre following the recent competitive designation process. The designation comes into effect from 1 April 2020 and is for an initial period of five years.

The OAHP includes Oxford Health NHS FT, Oxford University Hospitals NHS FT, Oxford Brookes University and the University of Oxford, who have been working closely together for the last six years in key areas including clinical research, multi-disciplinary education and healthcare innovations supporting the local needs and identified priorities.

OAHP’s vision is to respond to major challenges facing healthcare such as healthy ageing, multimorbidity and mental health, antimicrobial resistance and the best use of digital tools to improve care and patient self-management.

The OAHP is currently focusing their staff, facilities and expertise to overcome the COVID-19 pandemic, and using the close collaborations between the partners to make rapid progress in areas such as clinical trials of new treatments for COVID-19 patients in the NHS.  Daily examples of the excellent work and progress in this area can be seen across the media, with partners joining colleagues across the UK and beyond.

Professor Sir John Bell, Chairman of the OAHP said: “the strength of the partners and our plans are clear in all aspects of our work and our commitment to improve every aspect of patient care, research, innovation, education and training in ways that will benefit the changing NHS and its patients as a whole.”

Professor Keith Channon, Director of the OAHP, said: “This success reflects very strong working relationships between the Partners and the intention is now to deliver even more for current challenges, ongoing patient care, and in teaching, education and training and research and innovation.”

“Each partner has its own special set of skills and areas of expertise and together the OAHP can bring these together and work not only across Oxfordshire but regionally and nationally.”

Read more on the Oxford Academic Health Partners website

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.